Skip to main content

Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod

In the past decade, a variety of medications have come on the market to treat relapsing remitting multiple sclerosis (RRMS). Fingolimod, a functional antagonist of sphingosine 1-phosphate (S1P) receptors, reduces relapse frequency, MRI activity and disease progression. However, several side effects have been described – notably, heart block, macular edema, transaminitis, and infections. Varicella-zoster virus (VZV) cutaneous reactivation (shingles) is a well-known complication, but VZV vasculopathy has only been reported once [1].

from Journal of the Neurological Sciences https://ift.tt/2KELgGx
Labels:

Comments

Post a Comment

Popular posts from this blog

Reading Minds to Understand Human Tool Use

Combining brain imaging data with machine learning, researchers make new discoveries about how the brain controls the hand. The findings could lead to the development of more advanced neuroprosthetics. from Neuroscience News https://ift.tt/3tv7BbC
Post a Comment
Read more

Rethinking the Link Between Cannabinoids and Learning

Disrupted cannabinoid signaling impairs learning by altering behavioral states. from Neuroscience News https://ift.tt/2Hrmr0g
Post a Comment
Read more